Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: J Hepatol. 2022 Feb 12;77(1):55–62. doi: 10.1016/j.jhep.2022.01.027

Fig. 2. Incremental cost-effectiveness ratios of biannual HCC surveillance.

Fig. 2.

(A) In patients with cirrhosis and (B) in patients with advanced fibrosis who achieved virological cure with direct-acting antivirals. In patients with cirrhosis, HCC surveillance is cost-effective up to approximately age 70 using a willingness-to-pay threshold of $150,000 per quality-adjusted life year. In patients with advanced fibrosis, HCC surveillance is cost-effective up to age 60. HCC, hepatocellular carcinoma.